We came across a bullish thesis on United Therapeutics Corporation on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on UTHR. United Therapeutics Corporation’s share was trading at $471.99 as of January 15th. UTHR’s trailing and forward P/E were 17.89 and 15.15 respectively according to Yahoo Finance.
Phovoir/Shutterstock.com
United Therapeutics Corporation is a commercial-stage biotechnology company built around treprostinil, a prostacyclin analogue that drives its leadership in pulmonary arterial hypertension through multiple differentiated delivery platforms, including Tyvaso, Tyvaso DPI, Remodulin, and Orenitram. Treprostinil’s mechanism of action enables direct pulmonary vasodilation, and United Therapeutics has successfully expanded its utility across PAH and PH-ILD, establishing a durable and highly profitable franchise.
The next major value driver is the expansion of Tyvaso into idiopathic pulmonary fibrosis without co-morbid pulmonary hypertension, a significantly larger indication with high unmet need. The ex-US TETON-2 Phase 3 trial met its primary endpoint, demonstrating preservation of lung function, suggesting treprostinil may offer anti-fibrotic benefits beyond hemodynamic effects. The ongoing TETON-1 study in the US and Canada is the critical catalyst that could support a supplemental NDA and materially expand the company’s addressable market to roughly 100,000 US patients.
Financially, United Therapeutics is exceptionally well positioned, with over $4 billion in cash and investments, strong operating cash flow exceeding $1.3 billion annually, and no reliance on external financing. This balance sheet strength allows the company to absorb litigation risk, fund R&D, and pursue ambitious long-term organ manufacturing initiatives while maintaining profitability.
While competitive pressure from Liquidia and others may affect near-term dynamics within inhaled treprostinil, United Therapeutics’ multi-modal platform, entrenched patient support infrastructure, and clinical execution provide meaningful competitive insulation. With TETON-1 representing a clear inflection point and downside protected by a strong core franchise, United Therapeutics offers an attractive risk-reward skew for investors willing to underwrite near-term clinical risk.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy’s commercial potential, early patient uptake, insurance reimbursement progress, and a strong gene-editing pipeline. CRSP’s stock has appreciated by approximately 32% since our coverage. United Therapeutics Corporation (UTHR) shares a similar bullish view but emphasizes growth from treprostinil’s expansion into idiopathic pulmonary fibrosis and the upcoming TETON-1 trial.
